

Cefotaxime sodium salt

Safety Data Sheet

according to Regulation (EC) No. 1907/2006 (REACH) with its amendment Regulation (EU) 2015/830
Date of issue: 03/01/2019 Version: 1.0

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Product form	: Substance
Substance name	: Cefotaxime sodium salt
IUPAC name	: (6R,7R)-3-(acetyloxymethyl)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
EC-No.	: 264-915-9
CAS-No.	: 64485-93-4
Product code	: 50013891
Formula	: C ₁₆ H ₁₇ N ₅ O ₇ S ₂ ·Na
Product group	: Raw material

1.2. Relevant identified uses of the substance or mixture and uses advised against

1.2.1. Relevant identified uses

Main use category	: Industrial use, Professional use
Industrial/Professional use spec	: Industrial For professional use only Laboratory chemicals

1.2.2. Uses advised against

No additional information available

1.3. Details of the supplier of the safety data sheet

Supplier

Scaffell Organics
Molekula Ltd
Lingfield Way
Darlington - England
T +44 (0) 1949 823777 / +44 (0) 7590 545705
info@molekula.com / kbowen@molekula.com - www.molekula.com

1.4. Emergency telephone number

Emergency number : +44 (0) 7590 545705

SECTION 2: Hazards identification

2.1. Classification of the substance or mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP]


Respiratory sensitisation, Category 1	H334
Skin sensitisation, Category 1	H317
Full text of H statements : see section 16	

Adverse physicochemical, human health and environmental effects

No additional information available

2.2. Label elements

Labelling according to Regulation (EC) No. 1272/2008 [CLP]

Hazard pictograms (CLP)	: 
	GHS08

Signal word (CLP)	: Danger
Hazard statements (CLP)	: H317 - May cause an allergic skin reaction. H334 - May cause allergy or asthma symptoms or breathing difficulties if inhaled.
Precautionary statements (CLP)	: P261 - Avoid breathing dust, fume, gas, mist, spray, vapours. P280 - Wear protective gloves, protective clothing, eye protection, face protection. P342+P311 - If experiencing respiratory symptoms: Call a doctor, a POISON CENTER. P231 - Handle and store contents under inert gas. P410 - Protect from sunlight. P411 - Store at temperatures not exceeding 8 °C. P235 - Keep cool.

2.3. Other hazards

No additional information available

Cefotaxime sodium salt

Safety Data Sheet

according to Regulation (EC) No. 1907/2006 (REACH) with its amendment Regulation (EU) 2015/830

SECTION 3: Composition/information on ingredients

3.1. Substances

Substance type : Mono-constituent

Name	Product identifier	%
Cefotaxime sodium salt	(CAS-No.) 64485-93-4 (EC-No.) 264-915-9	100

Full text of H-statements: see section 16

3.2. Mixtures

Not applicable

SECTION 4: First aid measures

4.1. Description of first aid measures

First-aid measures general	: Never give anything by mouth to an unconscious person. If possible show this sheet, if not available show packaging or label. Do not leave affected person unattended.
First-aid measures after inhalation	: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. Give oxygen or artificial respiration if necessary. If experiencing respiratory symptoms: Get medical advice/attention.
First-aid measures after skin contact	: After contact with skin, take off immediately all contaminated clothing, and wash immediately with plenty of water. Do not remove clothing if it sticks to the skin. If skin irritation occurs: Get medical advice/attention.
First-aid measures after eye contact	: Rinse immediately with plenty of water. Remove contact lenses, if present and easy to do. Continue rinsing. Obtain medical attention if pain, blinking or redness persists.
First-aid measures after ingestion	: Rinse mouth. Do NOT induce vomiting. Get medical advice/attention.

4.2. Most important symptoms and effects, both acute and delayed

Symptoms/effects	: May cause an allergic skin reaction. May cause sensitisation of susceptible persons.
Symptoms/effects after inhalation	: May cause allergy or asthma symptoms or breathing difficulties if inhaled.
Symptoms/effects after skin contact	: May cause an allergic skin reaction. irritation (itching, redness, blistering). Prolonged or repeated contact may cause skin to become dry.
Symptoms/effects after eye contact	: Dust from this product may cause eye irritation. redness, itching, tears.
Symptoms/effects after ingestion	: May produce an allergic reaction. Symptoms similar to those listed under inhalation. Ingestion may cause nausea, vomiting and diarrhea.

4.3. Indication of any immediate medical attention and special treatment needed

Treat symptomatically.

SECTION 5: Firefighting measures

5.1. Extinguishing media

Suitable extinguishing media	: Foam. Dry powder. Carbon dioxide. Water spray. Sand.
Unsuitable extinguishing media	: Do not use a heavy water stream.

5.2. Special hazards arising from the substance or mixture

Hazardous decomposition products in case of fire	: Carbon oxides (CO, CO ₂). Nitrogen oxides. Sulphur oxides.
--	--

5.3. Advice for firefighters

Precautionary measures fire	: Exposure to fire/heat: seal off low-lying areas. Keep container tightly closed and away from heat, sparks and flame.
Firefighting instructions	: Use water spray or fog for cooling exposed containers. Exercise caution when fighting any chemical fire. Prevent fire fighting water from entering the environment. Use extinguishing agent suitable for surrounding fire.
Protection during firefighting	: Do not enter fire area without proper protective equipment, including respiratory protection.
Other information	: Warn all persons of toxic hazard.

SECTION 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

General measures	: Isolate from fire, if possible, without unnecessary risk. No flames, no sparks. Eliminate all sources of ignition. Avoid dust formation.
------------------	--

6.1.1. For non-emergency personnel

Protective equipment	: Wear recommended personal protective equipment.
Emergency procedures	: Evacuate unnecessary personnel.
Measures in case of dust release	: Keep upwind. Ventilate the area thoroughly, especially low lying areas (basements, workpits etc).

6.1.2. For emergency responders

Protective equipment	: Equip cleanup crew with proper protection.
Emergency procedures	: Ventilate area.

Cefotaxime sodium salt

Safety Data Sheet

according to Regulation (EC) No. 1907/2006 (REACH) with its amendment Regulation (EU) 2015/830

6.2. Environmental precautions

Prevent entry to sewers and public waters. Notify authorities if liquid enters sewers or public waters.

6.3. Methods and material for containment and cleaning up

Methods for cleaning up : On land, sweep or shovel into suitable containers. Minimise generation of dust. Store away from other materials.

6.4. Reference to other sections

See Heading 8. Exposure controls and personal protection.

SECTION 7: Handling and storage

7.1. Precautions for safe handling

Additional hazards when processed : Handle under inert gas.
Precautions for safe handling : Provide local exhaust or general room ventilation. Avoid creating or spreading dust.
Hygiene measures : Take off immediately all contaminated clothing and wash it before reuse. Contaminated work clothing should not be allowed out of the workplace. Always wash hands after handling the product. Wash hands and other exposed areas with mild soap and water before eating, drinking or smoking and when leaving work. Do not eat, drink or smoke when using this product.

7.2. Conditions for safe storage, including any incompatibilities

Technical measures : Ensure adequate ventilation, especially in confined areas. Handle and store contents under inert gas. Protect from moisture.
Storage conditions : Keep only in the original container in a cool, well ventilated place away from : Direct sunlight, Heat sources. Keep container closed when not in use.
Incompatible products : Strong oxidisers.
Incompatible materials : Light sensitive. Sources of ignition. Direct sunlight. Heat sources.
Storage temperature : 2 - 8 °C
Storage area : Store in a dark area. Store in dry protected location to prevent any moisture contact.

7.3. Specific end use(s)

No additional information available

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

No additional information available

8.2. Exposure controls

Appropriate engineering controls:

Handle in accordance with good industrial hygiene and safety procedures. Provide local exhaust or general room ventilation.

Personal protective equipment:

Wear recommended personal protective equipment. Avoid all unnecessary exposure.

Hand protection:

The protective gloves to be used must comply with the specifications of the regulation 2016/425 and the resultant standard EN 374

Type	Material	Permeation	Thickness (mm)	Penetration	Standard
Disposable gloves	Nitrile rubber (NBR)	6 (> 480 minutes)	0.11		EN 374

Eye protection:

Emergency eye wash fountains should be available in the immediate vicinity of any potential exposure. Use eye protection according to EN 166, designed to protect against powders and dusts. Chemical goggles or safety glasses

Type	Use	Characteristics	Standard
Safety goggles, Face shield	Dust	With side shields	EN 166

Skin and body protection:

Emergency safety showers should be available in the immediate vicinity of any potential exposure. Keep suitable chemically resistant protective clothing readily available for emergency use

Type	Standard
Total impervious protective suits, gloves, and boots must be worn to prevent any contact with the product	EN ISO 13982

Respiratory protection:

Self contained breathing apparatus, in case of emergency. Where exposure through inhalation may occur from use, respiratory protection equipment is recommended

Cefotaxime sodium salt

Safety Data Sheet

according to Regulation (EC) No. 1907/2006 (REACH) with its amendment Regulation (EU) 2015/830

Device	Filter type	Condition	Standard
Respiratory protective device with a particle filter	Type P1, Type P2	Dust protection	EN 14387

Other information:

Do not eat, drink or smoke during use.

SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

Physical state	: Solid
Appearance	: Crystalline powder.
Molecular mass	: 478.46 g/mol
Colour	: off white to light yellow.
Odour	: No data available.
Odour threshold	: No data available
pH	: No data available
Relative evaporation rate (butylacetate=1)	: No data available
Melting point	: > 170 °C lit
Freezing point	: No data available
Boiling point	: No data available
Flash point	: No data available
Auto-ignition temperature	: No data available
Decomposition temperature	: No data available
Flammability (solid, gas)	: Non flammable.
Vapour pressure	: No data available
Relative vapour density at 20 °C	: No data available
Relative density	: No data available
Solubility	: soluble in water.
Log Pow	: No data available
Viscosity, kinematic	: No data available
Viscosity, dynamic	: No data available
Explosive properties	: No data available
Oxidising properties	: No data available
Explosive limits	: No data available

9.2. Other information

No additional information available

SECTION 10: Stability and reactivity

10.1. Reactivity

The product is non-reactive under normal conditions of use, storage and transport.

10.2. Chemical stability

Stable under recommended handling and storage conditions (see section 7).

10.3. Possibility of hazardous reactions

No dangerous reactions known under normal conditions of use.

10.4. Conditions to avoid

Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. Protect from sunlight.

10.5. Incompatible materials

Strong oxidizers.

10.6. Hazardous decomposition products

Under normal conditions of storage and use, hazardous decomposition products should not be produced. Thermal decomposition generates : Carbon oxides (CO, CO₂). Nitrogen oxides. Sulphur oxides.

SECTION 11: Toxicological information

11.1. Information on toxicological effects

Acute toxicity (oral)	: Not classified
Acute toxicity (dermal)	: Not classified
Acute toxicity (inhalation)	: Not classified

Cefotaxime sodium salt (64485-93-4)

LD50 oral rat	> 20000 mg/kg
Skin corrosion/irritation	: Not classified

Cefotaxime sodium salt

Safety Data Sheet

according to Regulation (EC) No. 1907/2006 (REACH) with its amendment Regulation (EU) 2015/830

Additional information	: Based on available data, the classification criteria are not met
Serious eye damage/irritation	: Not classified
Additional information	: Based on available data, the classification criteria are not met
Respiratory or skin sensitisation	: May cause allergy or asthma symptoms or breathing difficulties if inhaled. May cause an allergic skin reaction.
Germ cell mutagenicity	: Not classified
Additional information	: Based on available data, the classification criteria are not met
Carcinogenicity	: Not classified
Additional information	: Based on available data, the classification criteria are not met
Reproductive toxicity	: Not classified
Additional information	: Based on available data, the classification criteria are not met
STOT-single exposure	: Not classified
Additional information	: Based on available data, the classification criteria are not met
STOT-repeated exposure	: Not classified
Additional information	: Based on available data, the classification criteria are not met
Aspiration hazard	: Not classified
Additional information	: Based on available data, the classification criteria are not met
Potential adverse human health effects and symptoms	: Based on available data, the classification criteria are not met.

SECTION 12: Ecological information

12.1. Toxicity

Acute aquatic toxicity	: Not classified
Chronic aquatic toxicity	: Not classified

12.2. Persistence and degradability

Cefotaxime sodium salt (64485-93-4)

Persistence and degradability	No data available.
-------------------------------	--------------------

12.3. Bioaccumulative potential

Cefotaxime sodium salt (64485-93-4)

Bioaccumulative potential	No data available.
---------------------------	--------------------

12.4. Mobility in soil

No additional information available

12.5. Results of PBT and vPvB assessment

No additional information available

12.6. Other adverse effects

Additional information	: Avoid release to the environment.
------------------------	-------------------------------------

SECTION 13: Disposal considerations

13.1. Waste treatment methods

Product/Packaging disposal recommendations	: Dispose in a safe manner in accordance with local/national regulations. Dispose of contents/container to an approved waste disposal plant.
--	--

Ecology - waste materials	: Avoid release to the environment.
---------------------------	-------------------------------------

SECTION 14: Transport information

In accordance with ADR / RID / IMDG / IATA / ADN

ADR	IMDG	IATA	ADN	RID
14.1. UN number				
Not regulated	Not regulated	Not regulated	Not regulated	Not regulated
14.2. UN proper shipping name				
Not regulated	Not regulated	Not regulated	Not regulated	Not regulated
14.3. Transport hazard class(es)				
Not regulated	Not regulated	Not regulated	Not regulated	Not regulated
14.4. Packing group				
Not regulated	Not regulated	Not regulated	Not regulated	Not regulated

Cefotaxime sodium salt

Safety Data Sheet

according to Regulation (EC) No. 1907/2006 (REACH) with its amendment Regulation (EU) 2015/830

14.5. Environmental hazards

Not regulated

Not regulated

Not regulated

Not regulated

Not regulated

No supplementary information available

14.6. Special precautions for user

Overland transport

Not regulated

Transport by sea

Not regulated

Air transport

Not regulated

Inland waterway transport

Not regulated

Rail transport

Not regulated

14.7. Transport in bulk according to Annex II of Marpol and the IBC Code

Not applicable

SECTION 15: Regulatory information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

15.1.1. EU-Regulations

No REACH Annex XVII restrictions

Cefotaxime sodium salt is not on the REACH Candidate List

Cefotaxime sodium salt is not on the REACH Annex XIV List

Directive 2012/18/EU (SEVESO III)

15.1.2. National regulations

No additional information available

15.2. Chemical safety assessment

No chemical safety assessment has been carried out for the substance or the mixture by the supplier

SECTION 16: Other information

Data sources : REGULATION (EC) No 1272/2008 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006.

Other information : None.

Full text of H- and EUH-statements:

Resp. Sens. 1	Respiratory sensitisation, Category 1
Skin Sens. 1	Skin sensitisation, Category 1
H317	May cause an allergic skin reaction.
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled.

SDS EU (REACH Annex II)

This information is based on our current knowledge and is intended to describe the product for the purposes of health, safety and environmental requirements only. It should not therefore be construed as guaranteeing any specific property of the product